Peter Turrone
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Peter Turrone has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Gary Remington
Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada
3 shared publications- Shitij Kapur
Institute of Psychiatry, King's College London, London, UK
3 shared publications José N. Nobrega
Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada
2 shared publicationsAlastair J. Flint
1 shared publicationJosé N Nobrega
Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
1 shared publicationMary V Seeman
Tapscott Chair in Schizophrenia Studies, Centre for Addiction and Mental Health, Clarke Site; Professor, Department of Psychiatry, University of Toronto, Toronto, Ontario
1 shared publication
Latest Publications
- Open Access
- 7 May 2003
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 28 (8) , 1433-1439
Differential Effects of Within-Day Continuous Vs Transient Dopamine D2 Receptor Occupancy in the Development of Vacuous Chewing Movements (VCMs) in Rats
Accumulating evidence suggests that antipsychotics (APs) that lead to sustained blockade of dopamine D2 receptors are more likely to induce acute extrapyramidal side effects (EPS) compared to APs that only occupy D2 receptors transiently. It is unclear, however, whether a similar relationship exists for long-term AP-induced motoric side effects like tardive dyskinesia (TD). The objective of this study was to ascertain whether transient (via daily subcutaneous (s.c.) injections) vs continuous (via osmotic minipump) AP-induced D2 receptor occupancy differentially affects the development of haloperidol-induced vacuous chewing movements (VCMs), an animal model of TD. Six groups of 12 rats received 0.1, 0.25, or 1 mg/kg of haloperidol or vehicle (n=36) via osmotic minipump (to provide within-day sustained) or daily s.c. injection (within-day transient) for 8 weeks. VCMs were measured on a weekly basis and D2 occupancy levels were measured in vivo using [3H]-raclopride at the end of the experiment. Minipump-treated rats developed HAL dose-dependent D2 occupancies of 0.1 mg/kg/day (57%), 0.25 mg/kg/day (70%), and 1 mg/kg/day (88%). S.C.-treated rats also developed HAL dose-dependent D2 occupancies of 0.1 mg/kg/day (83% peak, 3% trough), 0.25 mg/kg/day (89% peak, 0% trough), and 1 mg/kg/day (94% peak, 17% trough). A total of 43% of rats given 0.25 and 1 mg/kg/day of HAL via minipump developed high VCMs compared to only 8% of the rats given the same doses via daily s.c. injections. The 0.1 mg/kg dose did not give rise to VCMs beyond vehicle levels regardless of the route of administration. These findings support the contention that D2 occupancy levels induced by chronic HAL must be high and sustained through the day before significant risk of VCMs, and perhaps also TD, emerges.
- 7 May 2003
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 28 (8) , 1433-1439
Open AccessDifferential Effects of Within-Day Continuous Vs Transient Dopamine D2 Receptor Occupancy in the Development of Vacuous Chewing Movements (VCMs) in Rats
Accumulating evidence suggests that antipsychotics (APs) that lead to sustained blockade of dopamine D2 receptors are more likely to induce acute extrapyramidal side effects (EPS) compared to APs that only occupy D2 receptors transiently. It is unclear, however, whether a similar relationship exists for long-term AP-induced motoric side effects like tardive dyskinesia (TD). The objective of this study was to ascertain whether transient (via daily subcutaneous (s.c.) injections) vs continuous (via osmotic minipump) AP-induced D2 receptor occupancy differentially affects the development of haloperidol-induced vacuous chewing movements (VCMs), an animal model of TD. Six groups of 12 rats received 0.1, 0.25, or 1 mg/kg of haloperidol or vehicle (n=36) via osmotic minipump (to provide within-day sustained) or daily s.c. injection (within-day transient) for 8 weeks. VCMs were measured on a weekly basis and D2 occupancy levels were measured in vivo using [3H]-raclopride at the end of the experiment. Minipump-treated rats developed HAL dose-dependent D2 occupancies of 0.1 mg/kg/day (57%), 0.25 mg/kg/day (70%), and 1 mg/kg/day (88%). S.C.-treated rats also developed HAL dose-dependent D2 occupancies of 0.1 mg/kg/day (83% peak, 3% trough), 0.25 mg/kg/day (89% peak, 0% trough), and 1 mg/kg/day (94% peak, 17% trough). A total of 43% of rats given 0.25 and 1 mg/kg/day of HAL via minipump developed high VCMs compared to only 8% of the rats given the same doses via daily s.c. injections. The 0.1 mg/kg dose did not give rise to VCMs beyond vehicle levels regardless of the route of administration. These findings support the contention that D2 occupancy levels induced by chronic HAL must be high and sustained through the day before significant risk of VCMs, and perhaps also TD, emerges.
- 1 January 2003
- Published by Springer Nature in Psychopharmacology
- Vol. 165 (2) , 166-171
The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats
Rationale. A dose–response relationship between dopamine D2 occupancy and acute extrapyramidal symptoms (EPS) has been well established. However, the link with the induction of tardive dyskinesia (TD) is less clear. Objectives. To ascertain the nature and extent of D2 receptor occupancy effects on haloperidol-induced vacuous chewing movements (VCMs) in a rat model of TD. Methods. Groups of eight rats received haloperidol decanoate injections corresponding to daily doses of 0, 0.08, 0.17, 0.33, or 1 mg/kg for 10–12 weeks. VCMs were measured on a weekly basis and D2 occupancy levels were measured in vivo using [3H]-raclopride at the end of the experiment. Results. Final VCM scores were significantly different between haloperidol doses (P=0.001). Moderate but significant correlations were found between dose and average VCM scores (r=0.69, P2 occupancy and average VCM scores (r=0.65, P2 occupancy below that. Conclusions. These results indicate that chronic haloperidol induces VCMs in a dose-dependent manner, with doses leading to high D2 occupancy increasing the likelihood of emergence of the VCM syndrome. While a certain level of D2 occupancy may be necessary for inducing VCMs, it is not sufficient in and of itself to induce the VCM syndrome.
- 1 January 2003
- Published by Springer Nature in Psychopharmacology
- Vol. 165 (2) , 166-171
The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats
Rationale. A dose–response relationship between dopamine D2 occupancy and acute extrapyramidal symptoms (EPS) has been well established. However, the link with the induction of tardive dyskinesia (TD) is less clear. Objectives. To ascertain the nature and extent of D2 receptor occupancy effects on haloperidol-induced vacuous chewing movements (VCMs) in a rat model of TD. Methods. Groups of eight rats received haloperidol decanoate injections corresponding to daily doses of 0, 0.08, 0.17, 0.33, or 1 mg/kg for 10–12 weeks. VCMs were measured on a weekly basis and D2 occupancy levels were measured in vivo using [3H]-raclopride at the end of the experiment. Results. Final VCM scores were significantly different between haloperidol doses (P=0.001). Moderate but significant correlations were found between dose and average VCM scores (r=0.69, P2 occupancy and average VCM scores (r=0.65, P2 occupancy below that. Conclusions. These results indicate that chronic haloperidol induces VCMs in a dose-dependent manner, with doses leading to high D2 occupancy increasing the likelihood of emergence of the VCM syndrome. While a certain level of D2 occupancy may be necessary for inducing VCMs, it is not sufficient in and of itself to induce the VCM syndrome.
- 1 May 2002
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 26 (3) , 361-380
The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D2 receptor occupancy?
- 1 May 2002
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 26 (3) , 361-380
The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D2 receptor occupancy?
- 1 January 2002
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 159 (1) , 133-135
Elevation of Prolactin Levels by Atypical Antipsychotics
OBJECTIVE: Atypical antipsychotics are thought not to elevate prolactin levels. The authors examined data suggesting that atypical antipsychotics do elevate prolactin levels but more transiently than typical antipsychotics. METHOD: Prolactin levels in 18 male patients with schizophrenia who were receiving atypical antipsychotics were monitored over the 24-hour period following administration of their daily oral dose of risperidone, olanzapine, or clozapine. RESULTS: The baseline prolactin levels in patients receiving risperidone (mean=27 ng/ml, SD=14) were abnormally high, but baseline prolactin levels in patients receiving olanzapine (mean=9 ng/ml, SD=5) and clozapine (mean=9 ng/ml, SD=5) were not high. All three atypical antipsychotics caused a doubling of prolactin levels over baseline levels 6 hours after medication administration. CONCLUSIONS: These data suggest that these atypical antipsychotics raise prolactin levels, although the increases with olanzapine did not reach statistical significance. Th...
- 1 January 2002
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 159 (1) , 133-135
Elevation of Prolactin Levels by Atypical Antipsychotics
OBJECTIVE: Atypical antipsychotics are thought not to elevate prolactin levels. The authors examined data suggesting that atypical antipsychotics do elevate prolactin levels but more transiently than typical antipsychotics. METHOD: Prolactin levels in 18 male patients with schizophrenia who were receiving atypical antipsychotics were monitored over the 24-hour period following administration of their daily oral dose of risperidone, olanzapine, or clozapine. RESULTS: The baseline prolactin levels in patients receiving risperidone (mean=27 ng/ml, SD=14) were abnormally high, but baseline prolactin levels in patients receiving olanzapine (mean=9 ng/ml, SD=5) and clozapine (mean=9 ng/ml, SD=5) were not high. All three atypical antipsychotics caused a doubling of prolactin levels over baseline levels 6 hours after medication administration. CONCLUSIONS: These data suggest that these atypical antipsychotics raise prolactin levels, although the increases with olanzapine did not reach statistical significance. Th...
- Open Access
- 1 April 2000
- Published by SAGE Publications in The Canadian Journal of Psychiatry
- Vol. 45 (3) , 288-290
Estrogen Receptor Activation and Tardive Dyskinesia
Objective: To undertake a selective review of the epidemiology, etiology, and treatment of tardive dyskinesia (TD), with emphasis on the potential influence of estrogen in its expression.Method: Both Medline and Psycinfo databases were used to search for articles with the following key words: tardive dyskinesia, humans, animals, dopamine, estrogen, estrogen replacement therapy, antioxidants and oxidative stress.Results: The studies reviewed here suggest that estrogen modulates dopamine-mediated behaviours and that it protects against oxidative stress-induced cell damage caused by long-term exposure to antipsychotic medication.Conclusions: Estrogen's multimodal role in the central nervous system may prove useful for the amelioration or prevention of TD. All the evidence suggests that a placebo-controlled, randomized trial with safer forms of estrogen should be conducted in postmenopausal women with TD.
- 1 April 2000
- Published by SAGE Publications in The Canadian Journal of Psychiatry
- Vol. 45 (3) , 288-290
Open AccessEstrogen Receptor Activation and Tardive Dyskinesia
Objective: To undertake a selective review of the epidemiology, etiology, and treatment of tardive dyskinesia (TD), with emphasis on the potential influence of estrogen in its expression.Method: Both Medline and Psycinfo databases were used to search for articles with the following key words: tardive dyskinesia, humans, animals, dopamine, estrogen, estrogen replacement therapy, antioxidants and oxidative stress.Results: The studies reviewed here suggest that estrogen modulates dopamine-mediated behaviours and that it protects against oxidative stress-induced cell damage caused by long-term exposure to antipsychotic medication.Conclusions: Estrogen's multimodal role in the central nervous system may prove useful for the amelioration or prevention of TD. All the evidence suggests that a placebo-controlled, randomized trial with safer forms of estrogen should be conducted in postmenopausal women with TD.